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Abstract  
We investigated the evolution of Pfcrt K76T mutation five years after the withdrawal of chloroquine in Burkina Faso. A total of 675 clinical isolates 
collected from October 2010 to September 2012 were successfully genotyped. Single nucleotide polymorphism in Pfcrt (codon 76) gene was 
analyzed. The prevalence of resistant Pfcrt 76T allele was 20.55%. There was a progressive decrease of the proportion of mutant type pfcrt T76 
from 2010 to 2012 (X2=5.508 p=0.0189). Our results suggest a progressive return of the wild type Pfcrt K76 in Burkina Faso but the prevalence of 
the mutants Pfcrt T76 still remains high. 
 
 
Pan African Medical Journal. 2015; 21:101 doi:10.11604/pamj.2015.21.101.6437 
This article is available online at: http://www.panafrican-med-journal.com/content/article/21/101/full/ 
 
© Paul Sondo et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution 














Pan African Medical Journal – ISSN: 1937- 8688   (www.panafrican-med-journal.com) 







Page number not for citation purposes 2 
Introduction 
 
Like several malaria endemic countries, Artesunate-Amodiaquine 
(ASAQ) and Artemether-Lumefantrine (AL) are the two 
combinations recommended in Burkina Faso for the treatment of 
uncomplicated malaria since the change of the national policy in 
2005. Nevertheless recently, there were reports on the decreasing 
sensitivity of ACTs recorded along the Thailand and Myanmar border 
[1]. More recently a study conducted in Burkina Faso showed a high 
Lumefantine inhibition concentration (IC50) five years after the 
policy change, suggesting a decreasing efficacy of one of the two 
artemisinin based combination therapies (ACTs) recommended in 
the country [2]. In such context the development of alternative 
therapies is needed to anticipate the worldwide expansion of the 
ACTs resistance reported in Asia. That includes the use of old drugs 
such as chloroquine (CQ) in combination with partner drugs. Indeed 
the combination Chloroquine-Azithomycin has showed promising 
results in pregnant women [3,4]. This is particularly important in a 
context where few studies particularly in Malawi and Kenya showed 
that CQ resistance (CQ-R) decreases few years after its withdrawn 
and its replacement by ACTs [5-7]. These findings raise the issue of 
the reintroduction of chloroquine in the panel of potential alternative 
therapies face to ACTs resistance in the future. In such context 
there is a need of investigating the evolution of CQ-R to document 
its sensitivity profile. However currently there is an ethical issue of 
testing CQ in vivo in patients while a good efficacy of ACTs is still 
reported [8]. The only existing tools to overcome this problem is 
either the ex vivo test or testing the CQ-R molecular makers and 
particularly the Pfcrt gene [9]. However, due to technical constraints 
of ex vivo tests, the latter seems to be the more appropriate tool. 
Thus our aim in this study was to investigate the prevalence of Pfcrt 





The study was carried out from October 2010 to September 2012 at 
two peripheral health facilities (Nanoro and Nazoanga) of the 
Nanoro health district (NHD) in Burkina Faso. This is part of a study 
entitled: "Pharmacovigilance for artemisinin-based combination 
treatments in Africa" which had one component aiming at assessing 
the effectiveness of artesunate-amodiaquine (Arsucam®) versus 
artemether-lumefantrine (Coartem®) with a molecular analysis of 
resistance markers nested to it. Details of the study methodology 
have been described in detail elsewhere (ClinicalTrials.gov 
Identifier: NCT01232530). For the current analysis, clinical isolates 
from day 0 were genotyped. DNA was extracted from dried blood 
spots using Qiagen Kit and restriction fragment length 
polymorphism was used to detect the Pfcrt K76T mutation. Data 
were analyzed using STATA 8 (Stata Corp. 2003). A Chi-square test 
was used to assess the temporal fluctuation of the proportions. A 
value of P < 0.05 was considered as statistically significant. The 
study was approved by Center Muraz Institutional Ethics Committee, 





Overall, 675 blood samples were genotyped. Ninety one samples 
(13.48%) carrying both wild and mutant Pfcrtalleles and for which 
related frequencies could not be determined were excluded. The 
prevalence of wild type PfcrtK76 was 79.45 % (464/584). The 
proportion of mutant type Pfcrt T76 was 20.55% (120/584). The 
temporal evolution of Pfcrt codon 76 genotype profiles showed a 
decrease of the prevalence of the mutant type while those of the 
wild type increased progressively (Figure 1). From 2010 to 2012, 
the prevalence of the mutants Pfcrt T76 dropped from 27.22% 
(46/169) to 16.49% (16/97) while the prevalence of the wild type 
PfcrtK76 increased from 72.78% (123/169) to 83.51% (81/97) 
showing then a resurgence of CQ sensitive P. falciparumisolates in 





Our study aimed at assessing if parasites resistance profile has been 
affected by the implementation of the new treatment policies. 
Before the policy change, several studies have reported a high level 
of mutants Pfcrt T76 allele up to 65% in the country [10]. This 
study shows a decrease of this mutation five years after the 
withdrawal of chloroquine. Indeed, the prevalence reported in our 
study represents about half of that reported five years earlier and 
confirms the decrease of ex vivo CQ-R rate reported by Tinto et al in 
Bobo-Dioulasso at the same period [2]. These findings suggest that 
CQ-R may be decreasing following the implementation of the new 
anti-malarial drug policy using ACTs in Burkina Faso. Similar findings 
have been reported in many African countries and particularly in 
Malawi where, no CQ-R was found nine years after the with drawn 
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of CQ [5,6]. Nevertheless, the proportion reported in our study is 
still high compared to that reported in Malawi. This difference can 
be explained by several factors including the short duration between 
the introduction of the new treatment policy and our study which 
occurred only five years later when in Malawi it was nine years. In 
addition the use of Amodiaquine as partner drug in the combination 
ASAQ that is widely used in the country could lead to a selective 
pressureof Pfcrt T76mutant allele due to its similar chemical 
structure with chloroquine. Indeed the positive correlation between 
ex vivo IC50 values of CQ and amodiaquine reported by several 
authors and more recently by Tinto et al in Bobo-Dioulasso at the 
same period indicates cross-resistance and may also explain the still 





There is a progressive return of the wild type Pfcrt K76 in Burkina 
Faso but the prevalence of the mutants Pfcrt T76 is still high. 
Considering that, the possible reintroduction of CQ in the potential 
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Figure 1: Temporal evolution of Pfcrt (codon 76) genotypes 
profiles; the figure 1 represents the temporal evolution of Pfcrt 
codon 76 genotypes profiles from 2010 to 2012. The figure shows a 
progressive decrease of the mutants Pfcrt T76 (in red) whilst an 
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Figure 1: Temporal evolution of Pfcrt (codon 76) genotypes profiles; the figure 1 represents the temporal evolution 
of Pfcrt codon 76 genotypes profiles from 2010 to 2012. The figure shows a progressive decrease of the mutants 
Pfcrt T76 (in red) whilst an increase of the wild type PfcrtK76 (in blue) is observed 
 
